Status:
COMPLETED
Hereditary Spherocytosis and Vascular Function
Lead Sponsor:
Hospices Civils de Lyon
Conditions:
Hereditary Spherocytosis
Eligibility:
All Genders
6+ years
Phase:
NA
Brief Summary
Background : Patients with hereditary spherocytosis (HS) are characterized by increased red blood cell (RBC) fragility and a loss of RBC deformability. While the clinical variability of the disease ma...
Eligibility Criteria
Inclusion
- Healthy controls:
- age ≥ 6 years old
- written, informed and signed consent by the healthy volunteer, or by both parents or legal guardian if the healthy volunteer is a minor
- Healthy volunteer affiliated to a social security scheme or assimilated
- Healthy volunteer not subject to any legal protection measure
- Patients with hereditary spherocytosis:
- age ≥ 6 years old
- Patient with hereditary or non-splenectomized spherocytosis
- Written, informed and signed consent by the patient, or by at least one of the two parents or legal guardian if the patient is a minor
- Patient affiliated to a social security scheme or assimilated
- Patient not subject to any legal protection measure
Exclusion
- Healthy controls:
- Pregnant or lactating woman
- Subjects with hereditary spherocytosis or other characterized condition by chronic hemolysis
- Subjects with known pathology affecting the vascular system
- Blood donation (less than a month old)
- Not affiliated to a social security scheme
- Patient participating in another interventional research protocol that may interfere with this protocol (according to the investigator's judgment).
- Patients with hereditary spherocytosis:
- Patient who received a blood transfusion in the 3 months preceding
- Pregnant or lactating woman
- Any disease or condition other than hereditary spherocytosis, chronic or not, likely to induce chronic or acute intravascular hemolysis
- Patient participating in another interventional research protocol that may interfere with this protocol (according to the investigator's judgment).
Key Trial Info
Start Date :
August 26 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 26 2022
Estimated Enrollment :
72 Patients enrolled
Trial Details
Trial ID
NCT04451785
Start Date
August 26 2020
End Date
August 26 2022
Last Update
August 26 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Institut d'Hématologie et Oncologie PEdiatrique (iHOPe)
Lyon, France, 69373
2
Hôpital Edouard Herriot
Lyon, France, 69437